Увійти

Готові списки джерел за темами / 159.923.3:794.9 (043.2)

Зміст

Статті в журналах

Добірка наукової літератури з теми "159.923.3:794.9 (043.2)"

Автор: Grafiati

Опубліковано: 30 травня 2022

Оновлено: 31 липня 2025

Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями

Оберіть тип джерела:

Ознайомтеся зі списками актуальних статей, книг, дисертацій, тез та інших наукових джерел на тему "159.923.3:794.9 (043.2)".

Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.

Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.

Статті в журналах з теми "159.923.3:794.9 (043.2)"

1

Semenova, Lioubov I., and Allan H. White. "Structural Systematics of Rare Earth Complexes. XIX (Hydrated) 1 : 2 Mononuclear Adducts of Lanthanoid(III) Chlorides with 2,2′-Bipyridine and 1,10-Phenanthroline." Australian Journal of Chemistry 52, no. 6 (1999): 571. http://dx.doi.org/10.1071/ch98052.

Повний текст джерела

Анотація:

Room-temperature single-crystal X-ray structure determinations are recorded for a number of adducts of hydrated lanthanoid(III) trichlorides with 2,2′-bipyridine (‘bpy’) and 1,10-phenanthroline (‘phen’), crystallized from water, methanol or ethanol solutions, containing mononuclear arrays with 1 : 2 Ln/bpy or phen stoichiometry. LaCl3/phen/H2O(1 : 3 : 9), [(phen)2La(OH2)5]Cl3.phen.4H2O, although of overall 1 : 3 LaCl3/phen stoichiometry, has a lattice phen; it is orthorhombic, Pnna, a 19·947(7), b 16·457(5), c 12·213(2) Å, Z = 4; conventional R on |F| was 0·030 for No 2567 ‘observed’ (I >3σ

Стилі APA, Harvard, Vancouver, ISO та ін.

2

Gomes, Tiago Halyson de Oliveira, Welleson Feitosa Gazel, Emanuela Ferreira Goulart, Jennifer Lee Gonçalves, Gabriel Vargas Maia Chaves, and Lígia Luana Freire da Silva. "ÓBITOS DEVIDOS À SEPSE ESTREPTOCÓCICA NO BRASIL: ANÁLISE DE 13 ANOS." Revista ft 29, no. 143 (2025): 45–46. https://doi.org/10.69849/revistaft/ch10202502210945.

Повний текст джерела

Анотація:

Introdução: A sepse é uma síndrome caracterizada por uma resposta inflamatória exacerbada a uma infecção, levando à disfunção orgânica e risco elevado de morte. Fatores de risco como o uso de cateteres, sonda uretral, imunossupressão, comorbidades, infecções pré-existentes, resistência antimicrobiana e estado nutricional comprometido são determinantes importantes para o desenvolvimento da doença. Objetivos: O objetivo do presente trabalho é realizar o levantamento epidemiológico acerca dos óbitos por casos de septicemia estreptocócica no Brasil, em um período de 13 anos. Bem como realizar o le

Стилі APA, Harvard, Vancouver, ISO та ін.

3

Parker, Pablo M., Ryotaro Nakamura, Vinod Pullarket, et al. "Analysis of Predictive Power of Prednisone Dose at 3 Months of Treatment on CGVHD Prognosis." Blood 110, no. 11 (2007): 1975. http://dx.doi.org/10.1182/blood.v110.11.1975.1975.

Повний текст джерела

Анотація:

Abstract Current CGVHD prognostic and staging systems are still undergoing development and have identified plt count; CGVHD types progressive(P), quiescent(Q), de novo(DN); KPS, and GI involvement as significant risk factors affecting outcome. A simple reproducible staging system such as used for AGVHD to apply in clinical trials is still lacking. We evaluated whether the PSE dose required to control CGVHD at 3 months from diagnosis would have a prognostic effect on survival and in and of itself serve as a criteria for secondary intervention or investigational therapy. We hypothesized that by

Стилі APA, Harvard, Vancouver, ISO та ін.

4

Ritchlin, C. T., P. Rahman, P. Helliwell, et al. "AB0538 POOLED SAFETY RESULTS FROM TWO PHASE-3 TRIALS OF GUSELKUMAB IN PATIENTS WITH PSORIATIC ARTHRITIS THROUGH 1 YEAR." Annals of the Rheumatic Diseases 80, Suppl 1 (2021): 1300–1301. http://dx.doi.org/10.1136/annrheumdis-2021-eular.1334.

Повний текст джерела

Анотація:

Background:DISCOVER 1 & 2, two double-blind, phase-3, psoriatic arthritis (PsA) trials of guselkumab (GUS, an IL-23 inhibitor), demonstrated significant improvement with GUS vs placebo (PBO) in signs and symptoms of PsA, with good tolerability, at week (w) 24 during the PBO-controlled period.1,2 Beyond w24, all patients (pts) switched to GUS. Continued treatment maintained efficacy through w52.3,4Objectives:To describe pooled safety results from the DISCOVER 1 & 2 trials through 1-year of GUS treatment.Methods:Adults with active PsA (DISCOVER 1: ≥3 tender/swollen joints and C-Reactive

Стилі APA, Harvard, Vancouver, ISO та ін.

5

Matevosyan, Karén, Christopher Madden, Fleur M. Aung, et al. "Management of Warfarin Associated Intracranial Hemorrhage with a 3-Factor Prothrombin Complex Concentrate and Low Dose Recombinant Factor VIIa." Blood 112, no. 11 (2008): 3397. http://dx.doi.org/10.1182/blood.v112.11.3397.3397.

Повний текст джерела

Анотація:

Abstract Background: Intracranial hemorrhage (ICH) is a serious complication of warfarin therapy. Plasma infusion is the current standard of care in the US, even though most guidelines recommend prothrombin complex concentrate (PCC) as the preferred therapy; PCC has several advantages over plasma including no ABO blood type requirement, no lengthy thawing and infusion process, and a very small volume of virally inactivated pure vitamin K-dependent factors (VKDF) content that causes neither volume overload nor TRALI. Ideal PCC should contain adequate amounts of all VKDF (4-factor). As our group

Стилі APA, Harvard, Vancouver, ISO та ін.

6

Monteith, Bethany E., Esther Masih-Khan, Eshetu G. Atenafu, et al. "Patterns of Relapse and Progression in Multiple Myeloma Patients Treated with Conventional and Novel Agent-Based Therapy: A Single Centre Experience." Blood 126, no. 23 (2015): 5361. http://dx.doi.org/10.1182/blood.v126.23.5361.5361.

Повний текст джерела

Анотація:

Abstract Background The incorporation of novel agents (NA) for multiple myeloma (MM) has improved the response rates (RR), overall survival (OS), and progression free survival (PFS) when compared to conventional agents (CA). Unfortunately, relapse is inevitable and few studies focus on patterns of relapse, especially in non-transplant patients (pts). We aim to describe the different patterns of relapse in non-transplant MM pts and determine if any pre-treatment clinical or disease characteristics can predict the patterns relapse. We will evaluate whether NA treated pts have higher rates of agg

Стилі APA, Harvard, Vancouver, ISO та ін.

7

Molina Collada, J., F. Sánchez-Alonso, C. Bohórquez, et al. "OP0138 RISK OF CANCER AFTER BIOLOGIC AND TARGETED SYNTHETIC DMARDS INITIATION IN PATIENTS WITH RHEUMATIC DISEASES AND A HISTORY OF PRIOR MALIGNANCY: DATA FROM THE BIOBADASER REGISTRY." Annals of the Rheumatic Diseases 81, Suppl 1 (2022): 88.2–89. http://dx.doi.org/10.1136/annrheumdis-2022-eular.5030.

Повний текст джерела

Анотація:

BackgroundPatients with a history of cancer are routinely excluded from randomized controlled trials. As consequence, data on the safety of biologic disease modifying antirheumatic drugs (bDMARDS) and targeted synthetic (ts) DMARDs are limited. Although real world data from various national registries have not provided evidence of increased cancer recurrence, additional data from real-world registries may help to confirm safety of non-TNFi bDMARDs and tsDMARDs regarding cancer recurrence to guide treatment decisions.ObjectivesTo compare the risk of incident malignancy with exposure to differen

Стилі APA, Harvard, Vancouver, ISO та ін.

8

Sasaki, Koji, Elias Jabbour, Hagop M. Kantarjian, et al. "Outcome of Patients (pts) with Therapy-Related De Novo Acute Myeloid Leukemia (t-de novo AML): Single Institution Experience." Blood 124, no. 21 (2014): 2273. http://dx.doi.org/10.1182/blood.v124.21.2273.2273.

Повний текст джерела

Анотація:

Abstract Background: Therapy-related myeloid neoplasms develop after cytotoxic chemotherapy or radiation therapy. The available data on the outcome of pts with t-de novo AML without antecedent history of myelodysplastic syndrome (MDS) is limited. Methods: We reviewed the records of pts with newly diagnosed AML who presented to our tertiary care center from 1/2000 to 1/2014. t-de novo AML was defined as having at least 20% blasts in bone marrow with a history of any previous cytotoxic chemotherapy or radiation therapy, and without an antecedent history of MDS. Leukemia-free survival (LFS) was d

Стилі APA, Harvard, Vancouver, ISO та ін.

9

Magnus, Dan, Santosh Bhatta, and Julie Mytton. "432 Establishing injury surveillance in emergency departments in Nepal: epidemiology and burden of paediatric injuries." Emergency Medicine Journal 37, no. 12 (2020): 825.2–827. http://dx.doi.org/10.1136/emj-2020-rcemabstracts.7.

Повний текст джерела

Анотація:

Aims/Objectives/BackgroundGlobally, injuries cause more than 5 million deaths annually. Children and young people are a particularly vulnerable group and injuries are the leading cause of death in people aged 5–24 years globally and a leading cause of disability.In most low and middle-income countries where the majority of global child injury burden occurs, systems for routinely collecting injury data are limited. There is a continuing need for better data on childhood injuries and for injury surveillance.The aim of our study was to introduce a hospital-based injury surveillance tool – the fir

Стилі APA, Harvard, Vancouver, ISO та ін.

10

Palatianou, M., C. Tsentidis, M. Tzouvala, et al. "P0324 Lower Bone Mineral Density and alterations in bone biomarkers DKK-1, Sclerostin, and Periostin in individuals with Inflammatory Bowel Disease." Journal of Crohn's and Colitis 19, Supplement_1 (2025): i785. https://doi.org/10.1093/ecco-jcc/jjae190.0498.

Повний текст джерела

Анотація:

Abstract Background Inflammatory Bowel Disease (IBD) affects the gastrointestinal tract but often presents with extraintestinal manifestations in many patients, including the decline in bone mass. The pathogenesis of IBD is primarily attributed to disturbances in immune responses within the gastrointestinal mucosa and potential disruptions in gut microbiomes. The inflammation of gastrointestinal tract triggers various systems, including the Wnt pathway, which is associated with bone loss. This study explores the alterations in Bone Mineral Density (BMD) and the levels of dickkopf-1(DKK-1), scl

Стилі APA, Harvard, Vancouver, ISO та ін.

Більше джерел

Ми пропонуємо знижки на всі преміум-плани для авторів, чиї праці увійшли до тематичних добірок літератури. Зв'яжіться з нами, щоб отримати унікальний промокод!